BofA analyst Jason Zemansky upgraded Akero Therapeutics (AKRO) to Buy from Neutral with a $63 price target Invest with Confidence: Follow ...
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan ...
Akero Therapeutics Inc (AKRO) stock saw a modest uptick, ending the day at $54 which represents a slight increase of $2.53 or 4.92% from the prior close of $51.47. The stock opened at $52.48 and ...
Zacks.com on MSN23h
AKRO Stock Doubles in a Week as Lead Drug Meets Goal in MASH StudyAkero stock soars 106% in a week following initial positive top line 96-week data from a mid-stage MASH study of its lead ...
Akero's success in reversing cirrhosis follows that of Madrigal, making analysts and investors bullish on drugs to treat ...
Jefferies analyst Michael Yee increased the price target for Akero Therapeutics stock, listed on (NASDAQ:AKRO), to $75 from ...
Andrew Cheng, the President and CEO of Akero Therapeutics, Inc. (NASDAQ:AKRO), has recently disposed of shares worth approximately $1.65 million. According to a Form 4 filing with the Securities and ...
San Francsiscan liver specialist 89bio (Nasdaq: ETNB) has secured $250 million through a public stock offering, following a ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...
The big story of the day remains the Federal Reserve, which concludes its two-day FOMC meeting today and will announce its rate decision at 2:00pm New York time and then hold a press conference with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback